Cancer Treatment Regimen

About

1 in 8 U.S. women will develop invasive breast cancer in her lifetime. About 43,600 women and 480 men are expected to die from this disease in the U.S. in 2021. Despite improved diagnostics, breast cancer remains a devastating illness. It is critical to provide novel treatment options with no side effects for these patients. Researchers at Florida Atlantic University have developed a novel treatment regimen utilizing anti-parasitic agents (oxfendazole (OFZ) and parbenzadole (PBZ)) in combination with chitin microparticles to decrease/reverse metastatic breast disease and prolong survival. This regimen incorporates recruitment of off-target chitin microparticle (CMP) effects originating in the gut that reactivate the host immune responses to tumor cells with combination benzimidazoles (OFZ+PBZ) anti-tumor effects that inhibit tumor growth by decreasing tumor cell viability. The combination regimen will: (1) result in initial on-site tumor destabilization, (2) decrease tumor burden in primary tumor site and secondary metastatic loci, (3) prevent resistance to microtubule toxicity from developing in response to longer treatment plan, (4) equilibrate gut microbiota, and (5) re-orient the host innate and peripheral immune cells to target the tumor cells.